LncRNA ADAMTS9-AS1 knockdown suppresses cell proliferation and migration in glioma through downregulating Wnt/?-catenin signaling pathway

The long non-coding RNA antisense 1 ADAMTS9-AS1 has been reported to serve as an oncogene or tumor suppressor in several tumors, including colorectal cancer and hepatocellular carcinoma. Nevertheless, the clinical significance and biological behaviors of ADAMTS9-AS1 in glioma still remain unclear. Therefore, the goal of this study was to evaluate the functional roles and potential mechanisms of ADAMTS9-AS1 in glioma cells. Using quantitative real-time polymerase chain reaction analysis, we found that ADAMTS9-AS1 was upregulated in glioma tissues and cells in comparison to corresponding controls. ADAMTS9-AS1 expression level was correlated to tumor size (p = 0.005) and the World Health Organization grade (p = 0.002). Kaplan???Meier analysis and Cox multivariate analysis showed that ADAMTS9-AS1 could serve as an independent prognostic factor affecting the overall survival of glioma patients. Functionally, depletion of ADAMTS9-AS1 significantly suppressed the proliferation, migration, and invasion in glioma cell lines (U251 and U87), as shown through cell counting kit-8 assay, Edu corporation assay, wound healing assay, and transwell assay. Furthermore, we demonstrated that knockdown of ADAMTS9-AS1 suppressed Wnt1, ??-catenin, c-myc, and proliferating cell nuclear antigen, while upregulating E-cadherin expression. In conclusion, our data revealed that ADAMTS9-AS1 confers oncogenic function in the progression of glioma, thus targeting ADAMTS9-AS1 might be a promising therapeutic strategy for this disease.

Automated summary

The long non-coding RNA antisense 1 ADAMTS9-AS1 plays a role in the progression of glioma by promoting proliferation, migration, and invasion. It can serve as an independent prognostic factor affecting the overall survival of glioma patients. Targeting ADAMTS9-AS1 might be a potential therapeutic strategy for glioma.